Overview
- China’s National Medical Products Administration granted commercial clearance for the NEO implant in March 2026, moving the device beyond clinical trials toward routine use for selected patients.
- NEO was developed by Neuracle Technology with Tsinghua University and uses eight sensors placed on the dura mater to read brain signals and convert them into commands for assistive devices such as a soft robotic glove.
- Trial reports involving roughly three dozen participants show functional gains for some recipients, including a patient who regained the ability to hold a pen after surgery and months of rehabilitation.
- Days after approval the device received a code in China’s health insurance system and is reported to be entering mass production, which could broaden access through reimbursement and hospital adoption.
- Experts warn of medical risks such as infection and tissue damage and raise fresh concerns about who owns neural data and how implants will be secured against hacking, which could shape regulation and uptake.